Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNXNASDAQ:EMBCNASDAQ:LNSRNASDAQ:RXST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$15.36+6.4%$12.33$8.89▼$24.50$665.95MN/A479,143 shs270,215 shsEMBCEmbecta$10.45-0.9%$11.98$10.27▼$21.48$610.73M1.24466,128 shs798,503 shsLNSRLENSAR$13.72+1.0%$13.88$3.50▼$17.31$161.79M0.56147,323 shs58,309 shsRXSTRxSight$16.23+0.8%$16.57$12.53▼$61.10$659.54M1.32690,032 shs592,377 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics-3.48%-7.26%+33.61%-27.52%+1,442,999,900.00%EMBCEmbecta-6.31%-14.57%-14.37%-21.33%-19.40%LNSRLENSAR0.00%-2.86%-3.21%+24.93%+213.63%RXSTRxSight+0.56%+0.56%+10.58%-42.93%-73.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta BionicsN/AN/AN/AN/AN/AN/AN/AN/AEMBCEmbecta4.8296 of 5 stars3.25.03.30.02.63.33.8LNSRLENSAR1.3102 of 5 stars1.05.00.00.03.62.50.0RXSTRxSight3.0404 of 5 stars4.21.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.78Moderate Buy$24.8361.68% UpsideEMBCEmbecta 2.33Hold$19.3385.01% UpsideLNSRLENSAR 2.00Hold$15.009.33% UpsideRXSTRxSight 2.30Hold$37.90133.52% UpsideCurrent Analyst Ratings BreakdownLatest LNSR, RXST, EMBC, and BBNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/19/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $25.004/15/2025RXSTRxSightPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/9/2025RXSTRxSightUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$45.00 ➝ $16.004/4/2025RXSTRxSightJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Underweight$40.00 ➝ $17.004/3/2025RXSTRxSightWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $22.004/3/2025RXSTRxSightBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$36.00 ➝ $22.004/3/2025RXSTRxSightNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$69.83M9.54N/AN/AN/A∞EMBCEmbecta$1.08B0.57$2.42 per share4.32($13.23) per share-0.79LNSRLENSAR$57.07M2.84N/AN/A$2.97 per share4.62RXSTRxSight$148.31M4.45N/AN/A$4.47 per share3.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta BionicsN/AN/A0.00∞N/AN/AN/AN/AN/AEMBCEmbecta$78.30M$0.9010.453.400.785.25%-19.22%11.92%8/8/2025 (Estimated)LNSRLENSAR-$14.38M-$4.85N/A∞N/A-34.03%-49.02%-21.12%8/6/2025 (Estimated)RXSTRxSight-$48.61M-$0.67N/AN/AN/A-23.92%-14.00%-12.51%8/4/2025 (Estimated)Latest LNSR, RXST, EMBC, and BBNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/8/2025Q1 2025LNSRLENSAR-$0.1550-$2.32-$2.1650-$2.32$13.40 million$11.53 million5/7/2025Q1 2025RXSTRxSight-$0.03-$0.03N/A-$0.20$38.74 million$37.90 million5/6/2025Q1 2025BBNXBeta Bionics-$0.51-$0.52-$0.01-$0.93N/AN/A3/25/2025Q4 2024BBNXBeta Bionics-$0.42-$1.82-$1.40-$2.72$20.01 million$20.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/AEMBCEmbecta$0.605.74%N/A66.67%N/ALNSRLENSARN/AN/AN/AN/AN/ARXSTRxSightN/AN/AN/AN/AN/ALatest LNSR, RXST, EMBC, and BBNX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/AN/AN/AEMBCEmbectaN/A2.241.67LNSRLENSARN/A3.372.10RXSTRxSightN/A12.6711.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/AEMBCEmbecta93.83%LNSRLENSAR40.15%RXSTRxSight78.78%Insider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/AEMBCEmbecta0.42%LNSRLENSAR38.52%RXSTRxSight9.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.36 millionN/AN/AEMBCEmbecta1,90058.44 million57.89 millionOptionableLNSRLENSAR11011.79 million7.14 millionOptionableRXSTRxSight22040.64 million36.53 millionOptionableLNSR, RXST, EMBC, and BBNX HeadlinesRecent News About These CompaniesRxSight, Inc. (NASDAQ:RXST) Shares Sold by Two Sigma Investments LPMay 29 at 3:58 AM | marketbeat.comPolar Asset Management Partners Inc. Buys Shares of 46,700 RxSight, Inc. (NASDAQ:RXST)May 28 at 5:36 AM | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by D. E. Shaw & Co. Inc.May 28 at 3:26 AM | marketbeat.comTwo Sigma Advisers LP Sells 74,800 Shares of RxSight, Inc. (NASDAQ:RXST)May 27 at 4:23 AM | marketbeat.comRoyal Bank of Canada Raises Holdings in RxSight, Inc. (NASDAQ:RXST)May 27 at 4:13 AM | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Acquired by Voloridge Investment Management LLCMay 26 at 4:45 AM | marketbeat.comRxSight (NASDAQ:RXST) Stock Price Down 4.7% - What's Next?May 25, 2025 | marketbeat.comTwinbeech Capital LP Reduces Holdings in RxSight, Inc. (NASDAQ:RXST)May 25, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Receives $37.90 Average PT from AnalystsMay 24, 2025 | americanbankingnews.comDo Options Traders Know Something About RxSight Stock We Don't?May 23, 2025 | msn.comRxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Hold" by BrokeragesMay 23, 2025 | marketbeat.comSilvercrest Asset Management Group LLC Invests $2.99 Million in RxSight, Inc. (NASDAQ:RXST)May 22, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Upgraded to Overweight at Wells Fargo & CompanyMay 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Reduces Holdings in RxSight, Inc. (NASDAQ:RXST)May 21, 2025 | marketbeat.com5RXST : Deep Dive Into RxSight Stock: Analyst Perspectives (13 Ratings)May 20, 2025 | benzinga.comRxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology ForumMay 20, 2025 | globenewswire.comPolar Asset Management Partners Inc. Makes New Investment in RxSight, Inc. (NASDAQ:RXST)May 19, 2025 | marketbeat.comPolar Capital Holdings Plc Purchases 39,347 Shares of RxSight, Inc. (NASDAQ:RXST)May 18, 2025 | marketbeat.comNorthern Trust Corp Raises Stock Holdings in RxSight, Inc. (NASDAQ:RXST)May 18, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Purchased by Lazard Asset Management LLCMay 17, 2025 | marketbeat.comEnsign Peak Advisors Inc Purchases 27,913 Shares of RxSight, Inc. (NASDAQ:RXST)May 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLNSR, RXST, EMBC, and BBNX Company DescriptionsBeta Bionics NASDAQ:BBNX$15.36 +0.93 (+6.44%) As of 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Embecta NASDAQ:EMBC$10.45 -0.10 (-0.95%) Closing price 04:00 PM EasternExtended Trading$10.45 0.00 (0.00%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.LENSAR NASDAQ:LNSR$13.72 +0.14 (+1.03%) Closing price 04:00 PM EasternExtended Trading$13.71 -0.01 (-0.07%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.RxSight NASDAQ:RXST$16.23 +0.13 (+0.81%) Closing price 04:00 PM EasternExtended Trading$16.24 +0.01 (+0.07%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
